SDC 4: TABLE. Medically Attended Lower Respiratory Illnesses by Subject
No. Days
Treatment MA-LRI Virus Relationship to From Last
Subject No. Group Term Detected Study Vaccine Dose of Study
Vaccine
(Dose #)
4
Cohort 1 (10 TCID50) – MA-LRI events ≤28 days after vaccination
1 Vaccine Croup PIV1 Possible 18 (1)
Expiratory
2 Vaccine RSV-A Remote 16 (3)
wheeze
3 Placebo Rales PIV2 None 15 (2)
4 Placebo Croup PIV1 Possible 1 (3)
4
Cohort 1 (10 TCID50) – MA-LRI events >28 days after vaccination
Croup None Possible 67 (1)
Bronchiolitis RSV-B Possible 43 (3)
1 Vaccine
Bronchiolitis/
PIV3 Remote 141 (3)
pneumonia
5 Vaccine Pneumonia None None 58 (3)
4 Placebo Bronchiolitis None Possible 42 (3)
5
Cohort 2 (10 TCID50) – MA-LRI events >28 days after vaccination
Expiratory
6 Vaccine None None 62 (2)
wheeze
7 Vaccine Rhonchi PIV2 None 103 (3)
8 Placebo Bronchiolitis None None 66 (3)
Croup None None 71 (3)
9 Placebo
Croup None None 86 (3)
RSV-B,
10 Placebo Pneumonia None 136 (3)
HSV
6
Cohort 3 (10 TCID50) – MA-LRI events ≤28 days after vaccination
11 Vaccine Bronchiolitis None Remote 18 (2)
Expiratory
12 Placebo None Remote 28 (1)
wheeze
6
Cohort 3 (10 TCID50) – MA-LRI events >28 days after vaccination
13 Vaccine Rhonchi PIV1 Remote 34 (2)
MA-LRI indicates medically attended lower respiratory illness; PIV1, parainfluenza virus type 1; PIV2,
parainfluenza virus type 2; PIV3, parainfluenza virus type 3; RSV-A, respiratory syncytial virus type A;
RSV-B, respiratory syncytial virus type B; HSV, herpes simplex virus.